Abilify (aripiprazole) is an atypical antipsychotic. It is used, sometimes alone but more often in combination with other drugs, to treat schizophrenia, depression and other disorders in adults as well as irritability associated with autism and Tourette’s disorder in children. Abilify has been linked to impulse control disorders, including … [Read more...]
43 States and the District of Columbia Settle Abilify Lawsuit
On Thursday, Bristol-Myers Squibb agreed to settle a lawsuit including charges from 43 states and the District of Columbia for $19.5 million. The charges brought in the lawsuit concern the marketing of Abilify, an atypical antipsychotic drug produced to treat multiple forms of bipolar, schizophrenia, and Tourette’s disorder. The Problem With … [Read more...]
Abilify Plaintiffs Seek to Consolidate Claims in Multidistrict Litigation
Depressed or suffering from schizophrenia? If you or someone you know has been under treatment for bipolar disorder, schizophrenia or depression, you may have been prescribed an antipsychotic drug. Abilify (aripoprozole) is one such drug. Developed by Otsuka Pharmaceuticals with the help of pharmaceutical giant Bristol Myers Squibb Co, the drug has … [Read more...]
Abilify Linked to Compulsive Gambling and Other Impulse-Control Problems
Abilify (aripiprazole) is an atypical antipsychotic that was approved by the U.S. Food and Drug Administration (FDA) in 2002 to treat schizophrenia. Over the years, it was approved to treat more conditions, including depression and bipolar disorder. In May, 2016, the FDA issued a safety warning announcing that the drug was associated with … [Read more...]
Recent Comments